In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 5.94 above Repligen Corp average.

Within Biotechnology & Pharmaceuticals industry 59 other companies have achieved higher Quick Ratio than Repligen in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 444 to 633.

Explain Quick Ratio?
How much Cash & cash equivalents RGEN�s has?
What are RGEN�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

RGEN Quick Ratio	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2
Y / Y Current Liabilities Change	27.52 %	-23.17 %	2.28 %	16.25 %	-34.67 %
Y / Y Cash & cash equivalent Change	14.33 %	12.52 %	1.36 %	-4.49 %	-12.39 %
Quick Ratio MRQ	5.94	7.46	6.51	6.7	6.63
RGEN's Total Ranking	# 633	# 444	# 238	# 225	# 272
Seq. Current Liabilities Change	29.74 %	-10.79 %	5.4 %	4.54 %	-21.83 %
Seq. Cash & cash equivalent Change	3.3 %	2.2 %	2.52 %	5.63 %	1.67 %

Quick Ratio second quarter 2026 Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 60
Healthcare Sector	# 267
Overall Market	# 633

Quick Ratio Statistics
High	Average	Low
14.37	5.54	1.35
(Sep 30 2019)		(Sep 30 2017)

Financial Statements
Repligen's Current Liabilities	$ 136 Millions	Visit RGEN's Balance sheet
Repligen's Cash & cash equivalent	$ 810 Millions	Visit RGEN's Balance sheet
Source of RGEN's Sales		Visit RGEN's Sales by Geography

Cumulative Repligen's Quick Ratio

RGEN's Quick Ratio for the trailling 12 Months

RGEN Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	3.51 %	-13.72 %	-16.42 %	-25.41 %	-51.58 %
Y / Y Cash & cash equivalent TTM Growth	5.56 %	-1.24 %	-6.66 %	-6.81 %	-0.82 %
Quick Ratio TTM	6.6	6.81	6.17	6.18	6.47
Total Ranking TTM	# 3587	# 2696	# 1891	# 1637	# 1992
Seq. Current Liabilities TTM Growth	6.66 %	-6.7 %	0.56 %	3.43 %	-11.09 %
Seq. Cash & cash equivalent TTM Growth	3.38 %	2.99 %	0.35 %	-1.19 %	-3.29 %

Quick ratio ranking by company, industry and sector >> Back to RGEN Financial Strength Comparisons >> Go to Compare RGEN Quick Ratio to its Competitors

On the trailing twelve months basis Due to growth in Current Liabilities in the Q2 2026 to $136.40 millions, cumulative Quick Ratio decreased to 6.6 above the RGEN average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 137 other companies have achieved higher Quick Ratio than Repligen. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 2696 to 3587.

Explain Quick Ratio?
How much Cash & cash equivalents RGEN�s has?
What are RGEN�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Biotechnology & Pharmaceuticals Industry	# 138
Healthcare Sector	# 858
Within the Market	# 3587

trailing twelve months Quick Ratio Statistics
High	Average	Low
12.3	4.43	1.43
(Jun 30 2020)		(Dec 31 2022)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Biotechnology & Pharmaceuticals Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
Kyverna Therapeutics Inc	16.10	$ 367.021 Millions	$ 22.802 Millions
Tectonic Therapeutic Inc	15.96	$ 227.068 Millions	$ 14.224 Millions
Candel Therapeutics Inc	15.89	$ 201.565 Millions	$ 12.685 Millions
Inhibikase Therapeutics Inc	15.50	$ 159.019 Millions	$ 10.260 Millions
Voyager Therapeutics Inc	13.75	$ 229.369 Millions	$ 16.685 Millions
Leonabio Inc	13.07	$ 102.167 Millions	$ 7.817 Millions
Lenz Therapeutics Inc	12.82	$ 220.651 Millions	$ 17.212 Millions
X4 Pharmaceuticals Inc	11.41	$ 220.874 Millions	$ 19.366 Millions
Quince Therapeutics Inc	11.30	$ 116.000 Millions	$ 10.262 Millions
Compass Therapeutics Inc	11.15	$ 179.879 Millions	$ 16.128 Millions
Odyssey Therapeutics, Inc.	10.98	$ 310.575 Millions	$ 28.295 Millions
Protara Therapeutics Inc	10.70	$ 142.494 Millions	$ 13.319 Millions
Engene Therapeutics Inc	9.79	$ 266.320 Millions	$ 27.209 Millions
Eikon Therapeutics Inc	9.61	$ 531.178 Millions	$ 55.296 Millions
Zura Bio Limited	9.46	$ 205.134 Millions	$ 21.690 Millions
4d Molecular Therapeutics Inc	9.16	$ 436.624 Millions	$ 47.673 Millions
Fate Therapeutics Inc	8.44	$ 275.141 Millions	$ 32.592 Millions
Monte Rosa Therapeutics Inc	8.32	$ 1,152.100 Millions	$ 138.548 Millions
Cullinan Therapeutics Inc	8.23	$ 334.500 Millions	$ 40.628 Millions
Prokidney Corp	7.99	$ 181.564 Millions	$ 22.710 Millions
In8bio Inc	7.97	$ 17.956 Millions	$ 2.254 Millions
Denali Therapeutics Inc	7.89	$ 710.471 Millions	$ 90.083 Millions
Redwoods Acquisition Corp	7.69	$ 9.300 Millions	$ 1.210 Millions
Cardiff Oncology Inc	7.04	$ 76.005 Millions	$ 10.797 Millions
Black Diamond Therapeutics Inc	6.98	$ 110.506 Millions	$ 15.843 Millions
Immunovant Inc	6.81	$ 797.798 Millions	$ 117.102 Millions
Scholar Rock Holding Corp	6.81	$ 492.088 Millions	$ 72.242 Millions
Fennec Pharmaceuticals Inc	6.66	$ 82.498 Millions	$ 12.394 Millions
Krystal Biotech Inc	6.64	$ 845.600 Millions	$ 127.397 Millions
Caribou Biosciences Inc	6.33	$ 113.800 Millions	$ 17.974 Millions

Date modified: 2026-09-26T07:09:41+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.